<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34177816</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-2392</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in endocrinology</Title>
          <ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms.</ArticleTitle>
        <Pagination>
          <StartPage>696386</StartPage>
          <MedlinePgn>696386</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">696386</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2021.696386</ELocationID>
        <Abstract>
          <AbstractText>Hürthle cell lesions have been a diagnostic conundrum in pathology since they were first recognized over a century ago. Controversy as to the name of the cell, the origin of the cell, and even which cells in particular may be designated as such still challenge pathologists and confound those treating patients with a diagnosis of "Hürthle cell" anything within the diagnosis, especially if that anything is a sizable mass lesion. The diagnosis of Hürthle cell adenoma (HCA) or Hürthle cell carcinoma (HCC) has typically relied on a judgement call by pathologists as to the presence or absence of capsular and/or vascular invasion of the adjacent thyroid parenchyma, easy to note in widely invasive disease and a somewhat subjective diagnosis for minimally invasive or borderline invasive disease. Diagnostic specificity, which has incorporated a sharp increase in molecular genetic studies of thyroid tumor subtypes and the integration of molecular testing into preoperative management protocols, continues to be challenged by Hürthle cell neoplasia. Here, we provide the improving yet still murky state of what is known about Hürthle cell tumor genetics, clinical management, and based upon what we are learning about the genetics of other thyroid tumors, how to manage expectations, by pathologists, clinicians, and patients, for more actionable, precise classifications of Hürthle cell tumors of the thyroid.</AbstractText>
          <CopyrightInformation>Copyright © 2021 McFadden and Sadow.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>McFadden</LastName>
            <ForeName>David G</ForeName>
            <Initials>DG</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Department of Internal Medicine, Department of Biochemistry, Program in Molecular Medicine, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sadow</LastName>
            <ForeName>Peter M</ForeName>
            <Initials>PM</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 CA240239</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Endocrinol (Lausanne)</MedlineTA>
        <NlmUniqueID>101555782</NlmUniqueID>
        <ISSNLinking>1664-2392</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536913">Thyroid cancer, Hurthle cell</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018249" MajorTopicYN="Y">Adenoma, Oxyphilic</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054629" MajorTopicYN="N">Genome, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024862" MajorTopicYN="N">Oxyphil Cells</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013965" MajorTopicYN="N">Thyroidectomy</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Hürthle cell</Keyword>
        <Keyword MajorTopicYN="Y">Hürthle cell carcinoma</Keyword>
        <Keyword MajorTopicYN="Y">oncocytic</Keyword>
        <Keyword MajorTopicYN="Y">thyroid</Keyword>
        <Keyword MajorTopicYN="Y">thyroid cancer</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34177816</ArticleId>
        <ArticleId IdType="pmc">PMC8223676</ArticleId>
        <ArticleId IdType="doi">10.3389/fendo.2021.696386</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Askanazy M. Pathologisch-Anatomische Beiträge Zur Kenntniss Des Morbus Basedowii, Insbesondere Uber Die Dabei Auftretende Muskelerkrankkung. Dtsch Arch Klin Med (1898) 61:118–86.</Citation>
        </Reference>
        <Reference>
          <Citation>
Tremblay G, Pearse AG. Histochemistry of Oxidative Enzyme Systems in the Human Thyroid, With Special Reference to Askanazy Cells. J Pathol Bacteriol (1960) 80:353–8.  10.1002/path.1700800219
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.1700800219</ArticleId>
            <ArticleId IdType="pubmed">13777969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
LiVolsi V, Baloch ZW, Sobrinho Simoes M, Tallini G. Hurthle (Oncocytic) Cell Tumours. Lyon: International Agency for Research on Cancer;  (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>
Chan JKC, Hirokawa M, Evans H, Williams ED, Osamura Y, Cady B, et al. . Follicular Adenoma. Lyon: International Agency for Research on Cancer;  (2004).</Citation>
        </Reference>
        <Reference>
          <Citation>
Sobrinho Simoes M, Asa SL, Kroll TG, Nikiforov Y, DeLellis R, Farid P, et al. . Follicular Carcinoma. Lyon: International Agency for Research on Cancer;  (2004).</Citation>
        </Reference>
        <Reference>
          <Citation>
Glomski K, Nose V, Faquin WC, Sadow PM. Metastatic Follicular Thyroid Carcinoma and the Primary Thyroid Gross Examination: Institutional Review of Cases From 1990 to 2015. Endocr Pathol (2017) 28:177–85.  10.1007/s12022-017-9483-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-017-9483-6</ArticleId>
            <ArticleId IdType="pubmed">28444500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Parameswaran R, Shulin Hu J, Min En N, Tan WB, Yuan NK. Patterns of Metastasis in Follicular Thyroid Carcinoma and the Difference Between Early and Delayed Presentation. Ann R Coll Surg Engl (2017) 99:151–4.  10.1308/rcsann.2016.0300
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1308/rcsann.2016.0300</ArticleId>
            <ArticleId IdType="pmc">PMC5392828</ArticleId>
            <ArticleId IdType="pubmed">27659362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim SK, Park I, Hur N, Choe JH, Kim JH, Kim JS. Patterns, Predictive Factors and Prognostic Impact of Multilevel Metastasis in N1b Papillary Thyroid Carcinoma. Br J Surg (2017) 104:857–67.  10.1002/bjs.10514
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bjs.10514</ArticleId>
            <ArticleId IdType="pubmed">28295219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jalaly JB, Baloch ZW. Hurthle-Cell Neoplasms of the Thyroid: An Algorithmic Approach to Pathologic Diagnosis in Light of Molecular Advances. Semin Diagn Pathol (2020) 37:234–42.  10.1053/j.semdp.2020.03.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.semdp.2020.03.004</ArticleId>
            <ArticleId IdType="pubmed">32444244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Siegmund S, Landa I, Wong KS, Barletta JA. Hurthle Cell Neoplasms. Diagn Histopathol (2021) 27:1–9.  10.1016/j.mpdhp.2021.03.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mpdhp.2021.03.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, et al. . Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach. Am J Surg Pathol (2007) 31:1256–64.  10.1097/PAS.0b013e3180309e6a
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e3180309e6a</ArticleId>
            <ArticleId IdType="pubmed">17667551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bai S, Baloch ZW, Samulski TD, Montone KT, LiVolsi VA. Poorly Differentiated Oncocytic (Hurthle Cell) Follicular Carcinoma: An Institutional Experience. Endocr Pathol (2015) 26:164–9.  10.1007/s12022-015-9367-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-015-9367-6</ArticleId>
            <ArticleId IdType="pubmed">25898815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dettmer M, Schmitt A, Steinert H, Moch H, Komminoth P, Perren A. Poorly Differentiated Oncocytic Thyroid Carcinoma–Diagnostic Implications and Outcome. Histopathology (2012) 60:1045–51.  10.1111/j.1365-2559.2012.04188.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2559.2012.04188.x</ArticleId>
            <ArticleId IdType="pubmed">22348590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dettmer MS, Schmitt A, Komminoth P, Perren A. Poorly Differentiated Thyroid Carcinoma : An Underdiagnosed Entity. Pathologe (2020) 41:1–8.  10.1007/s00292-019-0600-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00292-019-0600-9</ArticleId>
            <ArticleId IdType="pmc">PMC7286943</ArticleId>
            <ArticleId IdType="pubmed">31273418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Metovic J, Vignale C, Annaratone L, Osella-Abate S, Maletta F, Rapa I, et al. . The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression Profile. J Clin Endocrinol Metab (2020) 105(12):e4577–92.  10.1210/clinem/dgaa655
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/clinem/dgaa655</ArticleId>
            <ArticleId IdType="pubmed">32936917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hao Y, Duh QY, Kloos RT, Babiarz J, Harrell RM, Traweek ST, et al. . Identification of Hurthle Cell Cancers: Solving a Clinical Challenge With Genomic Sequencing and a Trio of Machine Learning Algorithms. BMC Syst Biol (2019) 13:27.  10.1186/s12918-019-0693-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12918-019-0693-z</ArticleId>
            <ArticleId IdType="pmc">PMC6450053</ArticleId>
            <ArticleId IdType="pubmed">30952205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, et al. . Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol (2019) 5:204–12.  10.1001/jamaoncol.2018.4616
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.4616</ArticleId>
            <ArticleId IdType="pmc">PMC6439562</ArticleId>
            <ArticleId IdType="pubmed">30419129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, et al. . The RET/PTC Oncogene Is Frequently Activated in Oncocytic Thyroid Tumors (Hurthle Cell Adenomas and Carcinomas), But Not in Oncocytic Hyperplastic Lesions. J Clin Endocrinol Metab (2002) 87:364–9.  10.1210/jcem.87.1.8180
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.87.1.8180</ArticleId>
            <ArticleId IdType="pubmed">11788677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Vries MM, Celestino R, Castro P, Eloy C, Maximo V, van der Wal JE, et al. . RET/PTC Rearrangement Is Prevalent in Follicular Hurthle Cell Carcinomas. Histopathology (2012) 61:833–43.  10.1111/j.1365-2559.2012.04276.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2559.2012.04276.x</ArticleId>
            <ArticleId IdType="pubmed">22803838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Doerfler WR, Nikitski AV, Morariu EM, Ohori NP, Chiosea SI, Landau MS, et al. . Molecular Alterations in Hurthle Cell Nodules and Preoperative Cancer Risk. Endocr Relat Cancer (2021) 28(5):301–9.  10.1530/ERC-20-0435
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-20-0435</ArticleId>
            <ArticleId IdType="pubmed">33792557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Endo M, Nabhan F, Angell TE, Harrell RM, Nasr C, Wei S, et al. . Letter to the Editor: Use of Molecular Diagnostic Tests in Thyroid Nodules With Hurthle Cell-Dominant Cytology. Thyroid (2020) 30:1390–2.  10.1089/thy.2020.0021
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2020.0021</ArticleId>
            <ArticleId IdType="pubmed">32228149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, et al. . Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell (2018) 34:256–70.e5.  10.1016/j.ccell.2018.07.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC6247912</ArticleId>
            <ArticleId IdType="pubmed">30107176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, et al. . Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy. J Clin Endocrinol Metab (2013) 98:E962–72.  10.1210/jc.2012-3539
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-3539</ArticleId>
            <ArticleId IdType="pmc">PMC5393465</ArticleId>
            <ArticleId IdType="pubmed">23543667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gopal RK, Kubler K, Calvo SE, Polak P, Livitz D, Rosebrock D, et al. . Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hurthle Cell Carcinoma. Cancer Cell (2018) 34:242–55.e5.  10.1016/j.ccell.2018.06.013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.06.013</ArticleId>
            <ArticleId IdType="pmc">PMC6121811</ArticleId>
            <ArticleId IdType="pubmed">30107175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schatz-Siemers N, Brandler TC, Oweity T, Sun W, Hernandez A, Levine P. Hurthle Cell Lesions on Thyroid Fine Needle Aspiration Cytology: Molecular and Histologic Correlation. Diagn Cytopathol (2019) 47:977–85.  10.1002/dc.24247
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.24247</ArticleId>
            <ArticleId IdType="pubmed">31293091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wong KS, Angell TE, Barletta JA, Krane JF. Hurthle Cell Lesions of the Thyroid: Progress Made and Challenges Remaining. Cancer Cytopathol (2020) 29(5):347–62.  10.1002/cncy.22375
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.22375</ArticleId>
            <ArticleId IdType="pubmed">33108684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Evangelisti C, de Biase D, Kurelac I, Ceccarelli C, Prokisch H, Meitinger T, et al. . A Mutation Screening of Oncogenes, Tumor Suppressor Gene TP53 and Nuclear Encoded Mitochondrial Complex I Genes in Oncocytic Thyroid Tumors. BMC Cancer (2015) 15:157.  10.1186/s12885-015-1122-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-015-1122-3</ArticleId>
            <ArticleId IdType="pmc">PMC4374372</ArticleId>
            <ArticleId IdType="pubmed">25880213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kasaian K, Chindris AM, Wiseman SM, Mungall KL, Zeng T, Tse K, et al. . MEN1 Mutations in Hurthle Cell (Oncocytic) Thyroid Carcinoma. J Clin Endocrinol Metab (2015) 100:E611–5.  10.1210/jc.2014-3622
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-3622</ArticleId>
            <ArticleId IdType="pmc">PMC4399284</ArticleId>
            <ArticleId IdType="pubmed">25625803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. . Genomic and Transcriptomic Hallmarks of Poorly Differentiated and Anaplastic Thyroid Cancers. J Clin Invest (2016) 126:1052–66.  10.1172/JCI85271
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI85271</ArticleId>
            <ArticleId IdType="pmc">PMC4767360</ArticleId>
            <ArticleId IdType="pubmed">26878173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer. J Clin Endocrinol Metab (2013) 98:E1852–60.  10.1210/jc.2013-2292
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-2292</ArticleId>
            <ArticleId IdType="pmc">PMC3816258</ArticleId>
            <ArticleId IdType="pubmed">23979959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wei S, LiVolsi VA, Montone KT, Morrissette JJ, Baloch ZW. PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma. Endocr Pathol (2015) 26:365–9.  10.1007/s12022-015-9403-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-015-9403-6</ArticleId>
            <ArticleId IdType="pubmed">26530486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pecce V, Verrienti A, Abballe L, Carletti R, Grani G, Falcone R, et al. . Loss of Function Setd2 Mutations in Poorly Differentiated Metastases From Two Hurthle Cell Carcinomas of the Thyroid. Cancers (Basel) (2020) 12(1892):1–15.  10.3390/cancers12071892
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12071892</ArticleId>
            <ArticleId IdType="pmc">PMC7409075</ArticleId>
            <ArticleId IdType="pubmed">32674319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saqcena M, Leandro-Garcia LJ, Maag JLV, Tchekmedyian V, Krishnamoorthy GP, Tamarapu PP, et al. . SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. Cancer Discov (2020) 11:1158–75.  10.1158/2159-8290.CD-20-0735
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-20-0735</ArticleId>
            <ArticleId IdType="pmc">PMC8102308</ArticleId>
            <ArticleId IdType="pubmed">33318036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wallace DC. Mitochondrial DNA Sequence Variation in Human Evolution and Disease. Proc Natl Acad Sci USA (1994) 91:8739–46.  10.1073/pnas.91.19.8739
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.91.19.8739</ArticleId>
            <ArticleId IdType="pmc">PMC44682</ArticleId>
            <ArticleId IdType="pubmed">8090716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wredenberg A, Wibom R, Wilhelmsson H, Graff C, Wiener HH, Burden SJ, et al. . Increased Mitochondrial Mass in Mitochondrial Myopathy Mice. Proc Natl Acad Sci USA (2002) 99:15066–71.  10.1073/pnas.232591499
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.232591499</ArticleId>
            <ArticleId IdType="pmc">PMC137544</ArticleId>
            <ArticleId IdType="pubmed">12417746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yeh JJ, Lunetta KL, van Orsouw NJ, Moore FD, Jr., Mutter GL, Vijg J, et al. . (mtDNA) Mutations in Papillary Thyroid Carcinomas and Differential mtDNA Sequence Variants in Cases With Thyroid Tumours. Oncogene (2000) 19:2060–6.  10.1038/sj.onc.1203537
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1203537</ArticleId>
            <ArticleId IdType="pubmed">10803467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Savagner F, Franc B, Guyetant S, Rodien P, Reynier P, Malthiery Y. Defective Mitochondrial ATP Synthesis in Oxyphilic Thyroid Tumors. J Clin Endocrinol Metab (2001) 86:4920–5.  10.1210/jcem.86.10.7894
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.86.10.7894</ArticleId>
            <ArticleId IdType="pubmed">11600563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zielke A, Tezelman S, Jossart GH, Wong M, Siperstein AE, Duh QY, et al. . Establishment of a Highly Differentiated Thyroid Cancer Cell Line of Hurthle Cell Origin. Thyroid (1998) 8:475–83.  10.1089/thy.1998.8.475
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.1998.8.475</ArticleId>
            <ArticleId IdType="pubmed">9669284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, et al. . Defective Oxidative Phosphorylation in Thyroid Oncocytic Carcinoma is Associated With Pathogenic Mitochondrial DNA Mutations Affecting Complexes I and III. Cancer Res (2006) 66:6087–96.  10.1158/0008-5472.CAN-06-0171
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-06-0171</ArticleId>
            <ArticleId IdType="pubmed">16778181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, et al. . Disruptive Mitochondrial DNA Mutations in Complex I Subunits Are Markers of Oncocytic Phenotype in Thyroid Tumors. Proc Natl Acad Sci USA (2007) 104:9001–6.  10.1073/pnas.0703056104
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0703056104</ArticleId>
            <ArticleId IdType="pmc">PMC1885617</ArticleId>
            <ArticleId IdType="pubmed">17517629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, et al. . Origins and Functional Consequences of Somatic Mitochondrial DNA Mutations in Human Cancer. Elife (2014) 3:1–28.  10.7554/eLife.02935
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.02935</ArticleId>
            <ArticleId IdType="pmc">PMC4371858</ArticleId>
            <ArticleId IdType="pubmed">25271376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gopal RK, Calvo SE, Shih AR, Chaves FL, McGuone D, Mick E, et al. . Early Loss of Mitochondrial Complex I and Rewiring of Glutathione Metabolism in Renal Oncocytoma. Proc Natl Acad Sci USA (2018) 115:E6283–90.  10.1073/pnas.1711888115
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1711888115</ArticleId>
            <ArticleId IdType="pmc">PMC6142220</ArticleId>
            <ArticleId IdType="pubmed">29915083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, et al. . Comprehensive Molecular Characterization of Mitochondrial Genomes in Human Cancers. Nat Genet (2020) 52:342–52.  10.1038/s41588-019-0557-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41588-019-0557-x</ArticleId>
            <ArticleId IdType="pmc">PMC7058535</ArticleId>
            <ArticleId IdType="pubmed">32024997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rainwater LM, Farrow GM, Hay ID, Lieber MM. Oncocytic Tumours of the Salivary Gland, Kidney, and Thyroid: Nuclear DNA Patterns Studied by Flow Cytometry. Br J Cancer (1986) 53:799–804.  10.1038/bjc.1986.135
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.1986.135</ArticleId>
            <ArticleId IdType="pmc">PMC2001404</ArticleId>
            <ArticleId IdType="pubmed">3718832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mazzucchelli L, Burckhardt E, Hirsiger H, Kappeler A, Laissue JA. Interphase Cytogenetics in Oncocytic Adenomas and Carcinomas of the Thyroid Gland. Hum Pathol (2000) 31:854–9.  10.1053/hupa.2000.8444
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/hupa.2000.8444</ArticleId>
            <ArticleId IdType="pubmed">10923924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Erickson LA, Jalal SM, Goellner JR, Law ME, Harwood A, Jin L, et al. . Analysis of Hurthle Cell Neoplasms of the Thyroid by Interphase Fluorescence in Situ Hybridization. Am J Surg Pathol (2001) 25:911–7.  10.1097/00000478-200107000-00009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-200107000-00009</ArticleId>
            <ArticleId IdType="pubmed">11420462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corver WE, Ruano D, Weijers K, den Hartog WC, van Nieuwenhuizen MP, de Miranda N, et al. . Genome Haploidisation With Chromosome 7 Retention in Oncocytic Follicular Thyroid Carcinoma. PLoS One (2012) 7:e38287.  10.1371/journal.pone.0038287
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0038287</ArticleId>
            <ArticleId IdType="pmc">PMC3365880</ArticleId>
            <ArticleId IdType="pubmed">22675538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Addie RD, Kostidis S, Corver WE, Oosting J, Aminzadeh-Gohari S, Feichtinger RG, et al. . Metabolic Reprogramming Related to Whole-Chromosome Instability in Models for Hurthle Cell Carcinoma. Sci Rep (2020) 10:9578.  10.1038/s41598-020-66599-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-66599-1</ArticleId>
            <ArticleId IdType="pmc">PMC7293353</ArticleId>
            <ArticleId IdType="pubmed">32533088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corver WE, Demmers J, Oosting J, Sahraeian S, Boot A, Ruano D, et al. . ROS-Induced Near-Homozygous Genomes in Thyroid Cancer. Endocr Relat Cancer (2018) 25:83–97.  10.1530/ERC-17-0288
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-17-0288</ArticleId>
            <ArticleId IdType="pubmed">29066502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Arbajian E, Koster J, Vult von Steyern F, Mertens F. Inflammatory Leiomyosarcoma Is a Distinct Tumor Characterized by Near-Haploidization, Few Somatic Mutations, and a Primitive Myogenic Gene Expression Signature. Mod Pathol (2018) 31:93–100.  10.1038/modpathol.2017.113
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2017.113</ArticleId>
            <ArticleId IdType="pubmed">28884746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. . Integrated Genomic Characterization of Adrenocortical Carcinoma. Nat Genet (2014) 46:607–12.  10.1038/ng.2953
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2953</ArticleId>
            <ArticleId IdType="pubmed">24747642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baker TG, Alden J, Dubuc AM, Welsh CT, Znoyko I, Cooley LD, et al. . Near Haploidization Is a Genomic Hallmark Which Defines a Molecular Subgroup of Giant Cell Glioblastoma. Neurooncol Adv (2020) 2:vdaa155.  10.1093/noajnl/vdaa155
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/noajnl/vdaa155</ArticleId>
            <ArticleId IdType="pmc">PMC7764500</ArticleId>
            <ArticleId IdType="pubmed">33392505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bovee JV, van Royen M, Bardoel AF, Rosenberg C, Cornelisse CJ, Cleton-Jansen AM, et al. . Near-Haploidy and Subsequent Polyploidization Characterize the Progression of Peripheral Chondrosarcoma. Am J Pathol (2000) 157:1587–95.  10.1016/S0002-9440(10)64796-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)64796-7</ArticleId>
            <ArticleId IdType="pmc">PMC1885743</ArticleId>
            <ArticleId IdType="pubmed">11073818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. . The Genomic Landscape of Hypodiploid Acute Lymphoblastic Leukemia. Nat Genet (2013) 45:242–52.  10.1038/ng.2532
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2532</ArticleId>
            <ArticleId IdType="pmc">PMC3919793</ArticleId>
            <ArticleId IdType="pubmed">23334668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Joshi S, Tolkunov D, Aviv H, Hakimi AA, Yao M, Hsieh JJ, et al. . The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Rep (2015) 13:1895–908.  10.1016/j.celrep.2015.10.059
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2015.10.059</ArticleId>
            <ArticleId IdType="pmc">PMC4779191</ArticleId>
            <ArticleId IdType="pubmed">26655904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, et al. . Whole Exome and Targeted Deep Sequencing Identify Genome-Wide Allelic Loss and Frequent SETDB1 Mutations in Malignant Pleural Mesotheliomas. Oncotarget (2016) 7:8321–31.  10.18632/oncotarget.7032
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7032</ArticleId>
            <ArticleId IdType="pmc">PMC4884995</ArticleId>
            <ArticleId IdType="pubmed">26824986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. . Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 30:363.  10.1016/j.ccell.2016.07.013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2016.07.013</ArticleId>
            <ArticleId IdType="pubmed">27505681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic Indications for Hurthle Cell Cancer. World J Surg (2004) 28:1266–70.  10.1007/s00268-004-7602-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00268-004-7602-2</ArticleId>
            <ArticleId IdType="pubmed">15517492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kushchayeva Y, Duh QY, Kebebew E, D’Avanzo A, Clark OH. Comparison of Clinical Characteristics at Diagnosis and During Follow-Up in 118 Patients With Hurthle Cell or Follicular Thyroid Cancer. Am J Surg (2008) 195:457–62.  10.1016/j.amjsurg.2007.06.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjsurg.2007.06.001</ArticleId>
            <ArticleId IdType="pubmed">18070728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sabra MM, Ghossein R, Tuttle RM. Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising From Follicular Cell-Derived Thyroid Cancer. Thyroid (2016) 26:518–24.  10.1089/thy.2015.0395
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2015.0395</ArticleId>
            <ArticleId IdType="pmc">PMC5076482</ArticleId>
            <ArticleId IdType="pubmed">26872102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stojadinovic A, Hoos A, Ghossein RA, Urist MJ, Leung DH, Spiro RH, et al. . Hurthle Cell Carcinoma: A 60-Year Experience. Ann Surg Oncol (2002) 9:197–203.  10.1007/BF02557374
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02557374</ArticleId>
            <ArticleId IdType="pubmed">11888879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sanders LE, Silverman M. Follicular and Hurthle Cell Carcinoma: Predicting Outcome and Directing Therapy. Surgery (1998) 124:967–74.  10.1016/S0039-6060(98)70036-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0039-6060(98)70036-4</ArticleId>
            <ArticleId IdType="pubmed">9854570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van Heerden JA, Hay ID, Goellner JR, Salomao D, Ebersold JR, Bergstralh EJ, et al. . Follicular Thyroid Carcinoma With Capsular Invasion Alone: A Nonthreatening Malignancy. Surgery (1992) 112:1130–6; discussion 1136-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1455315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu B, Wang L, Tuttle RM, Ganly I, Ghossein R. Prognostic Impact of Extent of Vascular Invasion in Low-Grade Encapsulated Follicular Cell-Derived Thyroid Carcinomas: A Clinicopathologic Study of 276 Cases. Hum Pathol (2015) 46:1789–98.  10.1016/j.humpath.2015.08.015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humpath.2015.08.015</ArticleId>
            <ArticleId IdType="pmc">PMC4981341</ArticleId>
            <ArticleId IdType="pubmed">26482605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pathak KA, Klonisch T, Nason RW, Leslie WD. Fdg-PET Characteristics of Hurthle Cell and Follicular Adenomas. Ann Nucl Med (2016) 30:506–9.  10.1007/s12149-016-1087-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12149-016-1087-6</ArticleId>
            <ArticleId IdType="pubmed">27221817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pryma DA, Schoder H, Gonen M, Robbins RJ, Larson SM, Yeung HW. Diagnostic Accuracy and Prognostic Value of 18F-FDG PET in Hurthle Cell Thyroid Cancer Patients. J Nucl Med (2006) 47:1260–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16883003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordonez NG, et al. . Prognostic Factors in Patients With Hurthle Cell Neoplasms of the Thyroid. Cancer (2003) 97:1186–94.  10.1002/cncr.11176
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.11176</ArticleId>
            <ArticleId IdType="pubmed">12599224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jillard CL, Youngwirth L, Scheri RP, Roman S, Sosa JA. Radioactive Iodine Treatment Is Associated With Improved Survival for Patients With Hurthle Cell Carcinoma. Thyroid (2016) 26:959–64.  10.1089/thy.2016.0246
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2016.0246</ArticleId>
            <ArticleId IdType="pubmed">27150319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Amouri W, Charfeddine S, Charfi S, Jardak I, Boudawara T, Guermazi F. Clinicopathological Features and Outcomes After Radioactive Iodine Treatment of Oncocytic Well-Differentiated Thyroid Carcinomas. Nucl Med Commun (2019) 40:888–93.  10.1097/MNM.0000000000001049
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MNM.0000000000001049</ArticleId>
            <ArticleId IdType="pubmed">31343615</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
